Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Flowinmunocell-Bioexocell Group
Barcelona, Catalonia, Spainflowinmunocell.cl ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Flowinmunocell-Bioexocell Group is a biotechnology company specializing in immuno-oncology and cell-free therapies. The company focuses on the development of dendritic cell-derived vesicles (DC-Vesicles) and phospholipoproteomic complexes (PLPC) for immune reprogramming in cancer. Their research emphasizes the stability and functional potency of these vesicles as an alternative to traditional cell-based therapies. They have developed the Structured Traceability and Immunophenotypic Platform (STIP) to standardize the classification of tumor responses. The group operates internationally with key locations in Spain and Chile.
- Therapeutic areas
- Oncology
- Modalities
- Exosome-based therapyBiologicCell-free therapyVesicle-based therapy
- Industry
- Biotech
02
Partnerships
OGRD AllianceOGRD ConsortiumBioclas
Beyond the preview
Go deeper on Flowinmunocell-Bioexocell Group.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Flowinmunocell-Bioexocell Group.